Eating Disorders in Type 1 Insulin-dependent Diabetes Patients

Prevalence of Eating Disorders in Adult Patients With Type I Diabetes and Insulin Pump Treatment

Sponsors

Lead Sponsor: Icadom

Collaborator: AGIR à Dom

Source Icadom
Brief Summary

The purpose of this study is to determine the prevalence of eating disorders in type 1 insulin-dependent diabetes patients

Detailed Description

The risk of developing an eating disorder is increased in type 1 diabetes patients and associated with a poor prognosis in terms of glycemic control, metabolic complications, degenerative complications, and mortality. Therefore the terminology "diabulimia" has emerged to characterize an eating disorder specific to type 1 insulin-dependent diabetes patients, with insulin under dosage with a view of losing or controlling weight and that can contribute to a deterioration of the body composition. The purpose of this study is to determine the prevalence of eating disorders in an adult cohort with type 1 insulin-dependent diabetes.

Overall Status Recruiting
Start Date August 3, 2020
Completion Date September 30, 2021
Primary Completion Date July 31, 2021
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Eating disorders in men and women at inclusion
Secondary Outcome
Measure Time Frame
Eating disorders in cohort at inclusion
Auto declared insulin under dosage at inclusion
Overall glycemia at inclusion
Basal/Bolus insulin ratio at inclusion
Boluses performed per day at inclusion
Body composition at inclusion
Continuous glycemic control at inclusion
Glycemic variability at inclusion
Adherence to the sensor at inclusion
Blood glucose monitoring at inclusion
Enrollment 200
Condition
Intervention

Intervention Type: Other

Intervention Name: cohort

Description: During a regular follow-up visit, the following data will be collected: questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ) impedancemetry insulin pump and sensor data collection

Arm Group Label: cohort

Eligibility

Criteria:

Inclusion Criteria: - Adult patient over 18 years of age with type 1 diabetes treated with a subcutaneous insulin pump - Patient followed up for a subcutaneous insulin pump treatment by the healthcare provider, participating in the study (Agir à Dom group). - Beneficiary of social security coverage. Exclusion Criteria: - Patient with type 2 diabetes or MODY diabetes - Patient wearing a pacemaker - Breastfeeding or pregnant woman - Deprived of liberty by judicial or administrative decision - Tutorship or curatorship

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Cécile Bétry, PhD Principal Investigator CHU Grenoble Alpes
Overall Contact

Last Name: Pauline Socquet

Phone: 0763236615

Email: [email protected]

Location
Facility: Status: Contact: Investigator: AGIR à dom. Pauline Socquet 0763236615 [email protected] Géraldine BERGEAUD Sub-Investigator Claudie TRIBOUILLER Sub-Investigator Magali DESMAREST Sub-Investigator Fanny LIEVAUX Sub-Investigator Audrey LISMONDE Sub-Investigator Audrey DUSART Sub-Investigator Sothearot IM Sub-Investigator Sandrine LAFORGE Sub-Investigator
Location Countries

France

Verification Date

August 2020

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: cohort

Type: Experimental

Description: adult patients with type 1 diabetes and insulin pump treatement. Duration of participation: 30 minutes

Acronym Diaboulimia
Patient Data Yes
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Intervention Model Description: cohort prosective monocentric

Primary Purpose: Other

Masking: None (Open Label)

Source: ClinicalTrials.gov